CHSY2 Blocking Peptide
- Known as:
- CHSY2 Blocking Peptide
- Catalog number:
- 33r-7264
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- CHSY2 Blocking Peptide
Related genes to: CHSY2 Blocking Peptide
- Gene:
- CHPF NIH gene
- Name:
- chondroitin polymerizing factor
- Previous symbol:
- -
- Synonyms:
- CSS2, CHSY2
- Chromosome:
- 2q35
- Locus Type:
- gene with protein product
- Date approved:
- 2008-01-29
- Date modifiied:
- 2015-09-11
Related products to: CHSY2 Blocking Peptide
Related articles to: CHSY2 Blocking Peptide
- An accumulation of evidence underscores the critical importance of both hypoxia and the immune microenvironment in driving the progression of osteosarcoma. Despite advancements in therapeutic strategies, osteosarcoma continues to pose a formidable challenge due to its aggressive nature and high metastatic potential. Nonetheless, the identification of reliable gene signatures that combine information on hypoxia and immune status to predict osteosarcoma prognosis remains an unmet need. - Source: PubMed
Publication date: 2026/06/20
Xie ShangfangYu WenyaoLin RunyeXin Songjian - Immune checkpoint blockade (ICB) therapy offers remarkable clinical advantages for various cancers, but many patients still fail to receive sustained benefits from this treatment. Tumor microenvironment (TME), a multifaceted ecosystem composed of tumor cells, stromal cells, immune cells, and extracellular matrix (ECM), is critical in determining clinical outcomes and ICB response. The major aim of the study was to classify the breast cancer (BRCA) TME into distinct subtypes to predict ICB response, and to uncover the molecular mechanisms involved. - Source: PubMed
Publication date: 2026/05/27
He ZimengXu YunshengWu Chunyan - Chondroitin sulfate (CS) proteoglycans are extended (-GlcAβ1,3GalNAcβ1,4-) co-polymers attached to cell surface and extracellular matrix core proteins that are further modified by extensive sulfation and epimerization. Four homologous proteins contribute to CS backbone synthesis (CHPF1, CHPF2, CHSY1, and CHSY3) and prior data suggests assembly of the proteins into heterocomplexes is required for function. Here we show by sequence alignment and structural modeling that all CHSYs and CHPFs contain an N-terminal CAZy GT31-like domain and a C-terminal GT7-like domain separated by a cystatin-like linker domain. Co-expression of one CHPF and one CHSY is required to form a soluble, functional heterodimeric CS synthase and structural modeling indicates all four potential CHSY-CHPF combinations can form equivalent heterodimeric complexes. Cryo-EM studies on CHSY3-CHPF1 confirm the structure, interface, and active site features predicted by the structural models. Enzymatic analyses of catalytic mutants demonstrate that only the glycosyltransferase domains in the CHSYs are responsible for polymer synthesis: the GT31 domain transfers β1,3-GlcA while the GT7 domain transfers β1,4-GalNAc. The corresponding CHPF domains do not contribute to polymer synthesis but stabilize the corresponding CHSY functional domains. Additional mutagenesis and modeling suggest that the bridging cystatin-like domains may contribute to efficient polymer synthesis. - Source: PubMed
Publication date: 2026/05/27
Tehrani DanielCortiella-Valls NilHuang ChinChapla DigantkumarZheng ZhifengVenkat AaryaO'Boyle BradyKannan NatarajanPerez CamiloMoremen Kelley W - Abnormal glycolysis is one of the hallmarks of cancer and plays a significant role in its progression. This study investigates the association between glycolysis genes and the progression of lung adenocarcinoma (LUAD). Utilizing various bioinformatics techniques, the research explores the heterogeneity of glycolysis genes in different LUAD cell types, identifies glycolysis-related prognostic signatures (GRPS). We obtained one training set for model construction from the Cancer Genome Atlas (TCGA) database, and also obtained four LUAD gene expression datasets as validation sets from the Gene Expression Omnibus (GEO) database. The single-cell RNA sequencing (scRNA seq) data also comes from the GEO database. Firstly, the "limma" R package was used to identify differentially expressed glycolysis related genes, and a machine learning computational framework composed of multiple combinations was used to preliminarily screen for glycolysis related prognostic markers (GRPS) in LUAD. Based on these GRPS, prognostic features were developed and validated through survival analysis, column chart development, and ROC curve analysis. The ssGSEA algorithm, ESTIMATE algorithm, and seven integrated computational algorithms from the TIMER 2.0 database were used to analyze the immune cell infiltration patterns of different risk groups. Analyze scRNA seq data to evaluate the distribution of GRPS and intercellular communication among various cell types, and further determine the core GRPS through the "hdWGCNA" and "ConstructNetwork" packages. In addition, we also evaluated the responsiveness of high and low-risk groups to 198 drugs using the "OncoPredict" software package. Result: We found that the glycolytic activity score of tumor tissue was significantly higher than that of normal tissue, and a total of 49 upregulated genes and 15 downregulated genes were selected from the total. Based on a machine learning computational framework, a total of 8 GRPS were screened, which constitute the prognostic features of LUAD patients. This feature demonstrates strong prognostic value, as confirmed by univariate and multivariate Cox regression analysis. Significant differences in tumor microenvironment (TME) immune infiltration were observed between high and low-risk groups. ScRNA seq revealed the distribution and expression of cell type specific GRPS, particularly in T cells, epithelial cells, and fibroblasts, while also revealing the strong cell-cell communication ability of the high GRPS group. The hdWGCNA analysis ultimately identified five core GRPS, namely DDIT4, FKBP4, CHPF, EFNA3, and B3GNT3. In addition, there are significant differences in sensitivity to most drugs between high-risk and low-risk cohorts, with WIKI4 and Lapatinib negatively correlated with risk scores, while Doramapimod and Niraparib positively correlated with risk scores. This study established a GRPS based risk feature for LUAD, demonstrating strong predictive power for prognosis assessment. The drug sensitivity results also provide drug guidance for the clinical application of this feature, all of which provide important clinical utility for the prognosis of LUAD. At the same time, the intercellular communication network was plotted based on the GRPS score, providing insights into the pathogenesis of LUAD and offering new ideas for developing targeted therapies and precision medicine methods. - Source: PubMed
Publication date: 2026/04/13
Tang YalanXiao JundanZhong XiaoweiChen Zhigang - We report the case of a 74-year-old man with recurrence of prostate adenocarcinoma (PSA: 0.21 ng/mL) after radical prostatectomy. PSMA-PET/CT revealed intense uptake (SUVmax: 7.5) in an osteolytic lesion of the right femoral neck. Surgery was undertaken to prevent pathologic fracture. Histopathologic findings were consistent with a giant cell tumor of bone (GCTB). PSMA is expressed in endothelial cells of tumor neovasculature, explaining uptake in nonprostatic bone tumors. The case we report demonstrates that PSMA-PET/CT reflects vascular activity and may mimic metastasis, as prostate cancer metastases are usually sclerotic but can present as lytic lesions in the early stages. - Source: PubMed
Publication date: 2026/03/23
Reichart JulienCross TumatariiTorrado CelineCouturier Olivier-François